Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.3865 USD
−22.46 M USD
0.00 USD
9.94 M
About MiNK Therapeutics, Inc.
Sector
Industry
CEO
Jennifer S. Buell
Website
Headquarters
New York
Founded
2017
FIGI
BBG012J84VS3
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of INKT is 0.6160 USD — it has decreased by −3.08% in the past 24 hours. Watch MiNK Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MiNK Therapeutics, Inc. stocks are traded under the ticker INKT.
INKT stock has fallen by −12.50% compared to the previous week, the month change is a −18.39% fall, over the last year MiNK Therapeutics, Inc. has showed a −40.77% decrease.
We've gathered analysts' opinions on MiNK Therapeutics, Inc. future price: according to them, INKT price has a max estimate of 9.00 USD and a min estimate of 4.00 USD. Watch INKT chart and read a more detailed MiNK Therapeutics, Inc. stock forecast: see what analysts think of MiNK Therapeutics, Inc. and suggest that you do with its stocks.
INKT reached its all-time high on Nov 1, 2021 with the price of 22.1550 USD, and its all-time low was 0.5700 USD and was reached on Oct 8, 2024. View more price dynamics on INKT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
INKT stock is 12.00% volatile and has beta coefficient of 0.66. Track MiNK Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is MiNK Therapeutics, Inc. there?
Today MiNK Therapeutics, Inc. has the market capitalization of 24.92 M, it has decreased by −5.56% over the last week.
Yes, you can track MiNK Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
MiNK Therapeutics, Inc. is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
INKT earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.08 USD resulting in a 37.55% surprise. The estimated earnings for the next quarter are −0.05 USD per share. See more details about MiNK Therapeutics, Inc. earnings.
MiNK Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
INKT net income for the last quarter is −1.81 M USD, while the quarter before that showed −2.70 M USD of net income which accounts for 33.13% change. Track more MiNK Therapeutics, Inc. financial stats to get the full picture.
No, INKT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 14, 2024, the company has 31.00 employees. See our rating of the largest employees — is MiNK Therapeutics, Inc. on this list?
Like other stocks, INKT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MiNK Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MiNK Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MiNK Therapeutics, Inc. stock shows the strong sell signal. See more of MiNK Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.